CSIMarket Company Name, Ticker, Industry, else..
 
Evoke Pharma Inc   (NASDAQ: EVOK)
 
Price: $11.0000 $0.04 0.365%
Day's High: $11 Week Perf: 0.64 %
Day's Low: $ 10.98 30 Day Perf: 2.9 %
Volume (M): 47,100 52 Wk High: $ 11.00
Volume (M$): $ 518 52 Wk Avg: $7.54
Open: $10.98 52 Wk Low: $4.23



 Market Capitalization (Millions $) 28
 Shares Outstanding (Millions) 3
 Employees 8
 Revenues (TTM) (Millions $) 14
 Net Income (TTM) (Millions $) -5
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Evoke Pharma Inc is a specialty pharmaceutical company that focuses on developing and commercializing therapeutic solutions for gastrointestinal diseases. The company’s lead product is Gimoti, a nasal spray used for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Evoke Pharma aims to provide innovative and convenient treatment options for patients suffering from these conditions.


   Company Address: 420 Stevens Avenue Solana Beach 92075 CA
   Company Phone Number: 345-1494   Stock Exchange / Ticker: NASDAQ EVOK


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMRX   -1.77%    
BHC        4.16% 
INDV   -1.2%    
MNK   -39.2%    
TEVA   -0.36%    
VTRS        1.15% 
• View Complete Report
   



Management Announcement

Evoke Pharmas Strategic Moves: Pioneering Gastroparesis Solutions Amid Market Transitions and Shareholder Enhancements

Published Thu, Dec 19 2024 1:31 PM UTC

In the ever-evolving landscape of pharmaceutical innovation, Evoke Pharma, Inc. (NASDAQ: EVOK) is carving out a significant niche as a leading provider of treatments for gastrointestinal (GI) disorders, particularly in the realm of gastroparesis. With their flagship product, GIMOTI (metoclopramide) nasal spray, gaining attention as a compelling alternative amidst shifting dy...
Stock Market Announcement

Evoke Pharma Initiates 1-for-12 Reverse Stock Split to Enhance Shareholder Value

Published Tue, Jul 30 2024 12:31 PM UTC


Date: August 1, 2024
SOLANA BEACH, Calif. - Evoke Pharma, Inc. (NASDAQ: EVOK), a pioneering specialty pharmaceutical company, announced today that its board of directors has approved a 1-for-12 reverse stock split of the company s common stock. This strategic move aims to enhance shareholder value and solidify Evoke Pharma s position in the market focused primarily ...
Management Announcement

Evoke Pharma: Seizing Opportunities to Revolutionize GI Therapeutics with Recent Underwritten Public Offering

Published Fri, Feb 9 2024 12:31 PM UTC


Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company specializing in gastrointestinal (GI) disease treatments, has recently disclosed the pricing details of its underwritten public offering. The company aims to raise gross proceeds of up to $30 million through this o...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 1.95
Price to Sales (Expected) -
Price to Book 8.37
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.95
Working Capital Ratio 1.27
Leverage Ratio (MRQ) 3.64
Total Debt to Equity 1.49
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.21 $
Revenues (TTM) 5.64 $
Cash Flow (TTM) 0.09 $
Cash 4.53 $
Book Value 1.31 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 1,803,082
Net Income per Employee (TTM) -653,266
Receivable Turnover Ratio (TTM) 5.23
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.88

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -26.56 %
Net Margin (MRQ) -26.99 %
Net Cash Flow Margin (MRQ) -11.28 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Evoke Pharma Inc's Segments
Pharmaceutical Products    100 % of total Revenue

  Evoke Pharma Inc Outlook

On May 14 2024 the Evoke Pharma Inc provided following guidance

Evoke Pharma Inc. has released its first quarter financial results for 2024, showing a significant 114% year-over-year ...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.